Eliglustat Tartrate Patent Expiration
Eliglustat Tartrate is used for long-term treatment of Gaucher disease type 1. It was first introduced by Genzyme Corp
Eliglustat Tartrate Patents
Given below is the list of patents protecting Eliglustat Tartrate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Cerdelga | US10888544 | Methods for treating Gaucher disease | Dec 13, 2038 | Genzyme Corp |
| Cerdelga | US10888547 | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase | Jan 31, 2031 | Genzyme Corp |
| Cerdelga | US11458119 | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase | Nov 24, 2030 | Genzyme Corp |
| Cerdelga | US7196205 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | Jun 26, 2026 | Genzyme Corp |
| Cerdelga | US6916802 | Amino ceramide-like compounds and therapeutic methods of use |
Apr 29, 2022
(Expired) | Genzyme Corp |
| Cerdelga | US7253185 | Amino ceramide-like compounds and therapeutic methods of use |
Apr 29, 2022
(Expired) | Genzyme Corp |
| Cerdelga | US7615573 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors |
Apr 29, 2022
(Expired) | Genzyme Corp |
Eliglustat Tartrate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List